載入中
HKSEHealthcareBiotechnology
最新資料
HK$3.80
−HK$0.20 · -5.00%
Beijing Biostar Pharmaceuticals Co. Ltd. primarily focuses on developing innovative therapies for tumors. The company is dedicated to creating novel anti-cancer drugs, each secured by independent intellectual property rights. A prominent product in its portfolio is the Utidelone injection, a next-generation microtubule inhibitor produced through a unique microbial fermentation process. This enterprise was co-founded by Li Tang and Rong Guo Qiu on July 11, 2002, and operates from its headquarters in Beijing, China.
最新資料
HK$3.80
−HK$0.20 · -5.00%
Beijing Biostar Pharmaceuticals Co. Ltd. primarily focuses on developing innovative therapies for tumors. The company is dedicated to creating novel anti-cancer drugs, each secured by independent intellectual property rights. A prominent product in its portfolio is the Utidelone injection, a next-generation microtubule inhibitor produced through a unique microbial fermentation process. This enterprise was co-founded by Li Tang and Rong Guo Qiu on July 11, 2002, and operates from its headquarters in Beijing, China.
52週區間
目前HK$3.80
歷史價格可能經過調整並有所延遲。
Beijing Biostar Pharmaceuticals Co. Ltd. primarily focuses on developing innovative therapies for tumors. The company is dedicated to creating novel anti-cancer drugs, each secured by independent intellectual property rights. A prominent product in its portfolio is the Utidelone injection, a next-generation microtubule inhibitor produced through a unique microbial fermentation process. This enterprise was co-founded by Li Tang and Rong Guo Qiu on July 11, 2002, and operates from its headquarters in Beijing, China.
52週區間
目前HK$3.80
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（HKD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 3711.77萬 HKD | 7791.83萬 HKD | 7375.18萬 HKD | 3737.91萬 HKD | 1.07億 HKD |
| 銷貨成本 | 290.02萬 HKD | 1047.12萬 HKD | 2192.58萬 HKD | 1018.19萬 HKD | 626.39萬 HKD |
| 毛利 | 3365.16萬 HKD | 6674.84萬 HKD | 5182.6萬 HKD | 2719.73萬 HKD | 1億 HKD |
| 研究與開發 | 9232.98萬 HKD | 1.24億 HKD | 1.4億 HKD | 7012.06萬 HKD | 1.4億 HKD |
| 銷售、一般及管理費用 | 4253.98萬 HKD | 4450.23萬 HKD | 1.54億 HKD | 1.16億 HKD | 3.28億 HKD |
| 營業費用 | 1.84億 HKD | 2.18億 HKD | 2.93億 HKD | 2.55億 HKD | 5.12億 HKD |
| 利息收入 | 510.09萬 HKD | 516.89萬 HKD | 1454.12萬 HKD | 380.51萬 HKD | — |
| 利息支出 | 10.28萬 HKD | 11.92萬 HKD | 6.31萬 HKD | 8.09萬 HKD | — |
| 折舊和攤銷 | 1161.7萬 HKD | 1053.6萬 HKD | 1175.65萬 HKD | 1196.09萬 HKD | 1065.53萬 HKD |
| 營業利益 | −1.51億 HKD | −1.84億 HKD | −2.41億 HKD | −2.28億 HKD | −4.11億 HKD |
| 淨利 | −1.43億 HKD | −1.56億 HKD | −2.1億 HKD | −1.83億 HKD | −4.18億 HKD |
公司資料更新於 2026年10月18日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
